Back to top
more

Galectin Therapeutics (GALT)

(Delayed Data from NSDQ)

$3.08 USD

3.08
278,102

+0.05 (1.65%)

Updated May 13, 2024 04:00 PM ET

After-Market: $3.07 -0.01 (-0.32%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GALT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Galectin Therapeutics Inc. [GALT]

Reports for Purchase

Showing records 21 - 40 ( 107 total )

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 21

04/16/2021

Company Report

Pages: 9

Published Data Show Belapectin Enhances Cancer Immunotherapy Response

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 22

12/04/2020

Daily Note

Pages: 3

Galectin Running Full Steam Ahead With Belapectin in Three Clinical Trials; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 23

11/11/2020

Company Report

Pages: 8

3Q20 Recap: Innovative Phase 2b/3 NASH-RX Study Continues Long Climb Towards Full Enrollment; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 24

10/02/2020

Industry Report

Pages: 58

Final Program for Our Fourth Annual Virtual NASH Investor Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 100.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 25

10/01/2020

Daily Note

Pages: 4

With NASH-RX Trial Underway, Investors Need Patience for Interim Analysis Expected in 2Q23; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 26

09/03/2020

Daily Note

Pages: 3

Director Joel Lewis Takes the Reins as CEO as Dr. Shlevin Retires; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 27

08/13/2020

Company Report

Pages: 8

2Q Recap: Looking Forward to the Interim Analysis of the Phase 2b/3 NASH-RX Trial; Raise PT to $12

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 28

03/17/2020

Company Report

Pages: 8

4Q19 Recap: Confident in Start of Phase 3 Cirrhotic NASH Trial in 2Q20; PT to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 29

11/13/2019

Company Report

Pages: 8

3Q19 NASH-RX Start Delayed by 3 Months But Our Thesis Remains Unchanged; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 30

10/15/2019

Industry Report

Pages: 49

Final Program for Our Third Annual NASH Investor Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 100.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 31

10/07/2019

Industry Report

Pages: 48

Program for Our Third Annual NASH Investor Conference, October 21, New York

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 100.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 32

08/12/2019

Company Report

Pages: 8

2Q19 Phase 3 NASH-RX Ready to Go, Just Awaiting Final OK from FDA; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 33

08/06/2019

Daily Note

Pages: 3

Phase 3 NASH-RX Protocol in Cirrhotic NASH Submitted to FDA; Initiation Expected in 4Q19; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 34

06/07/2019

Industry Report

Pages: 4

FDA Guidance for Cirrhotic NASH Strongly

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 35

05/29/2019

Company Report

Pages: 6

With Successful Rights Offering, Sole Focus Remains Initiating Phase 3 in 3Q19; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 36

05/14/2019

Company Report

Pages: 8

1Q19 Recap; We Believe the Rights Offering Will Be Successful; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 37

04/16/2019

Daily Note

Pages: 3

With the Phase 3 Design Set, the Rights Offering Is Underway; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 38

03/07/2019

Company Report

Pages: 8

Rights Offering Boosts Our Confidence; We See a Pivotal Readout Likely in 1Q22: Adjust PT to $11

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 39

02/12/2019

Industry Report

Pages: 3

NASH Splash No. 5: The STELLAR-4 Failure Is No Big Surprise to Us

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 40

01/16/2019

Daily Note

Pages: 3

Galectin Cleans up Balance Sheet and Related Covenants to Better Attract Outside Parties

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party